0035| Volume 128, SUPPLEMENT , 154997, March 2022

Liraglutide in Treatment of Diabetes Mellitus Type 2: Systematic Review and Bibliometric Analysis Over The Last Two Decades

      Background: Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disorder and liraglutide is one of the glucagon-like peptide-1 (GLP-1) agonists that are used to decrease glucose levels in the blood and help in weight loss in patients with T2DM. Bibliometric analysis is one of the most common statistical methods used to evaluate the credibility, quality, and impact of scholarly work.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect